Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Venkatesh Goura

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
European Journal of Pharmacology|May 11, 2013
α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for painRamakrishna Nirogi, Venkatesh Goura, Renny Abraham, et al.
Behavioural Pharmacology|October 14, 2025
5-Hydroxytryptamine 7 receptor agonist LP-211 in combination with gabapentin ameliorates neuropathic pain comorbidities associated with mechanical allodynia in diabetic and nerve-ligated ratsVenkatesh Goura, Pradeep Jayarajan, Anoop Kishore, et al.
Journal of Pharmacological and Toxicological Methods|May 12, 2012
Comparison of manual and automated filaments for evaluation of neuropathic pain behavior in ratsRamakrishna Nirogi, Venkatesh Goura, Dhanalakshmi Shanmuganathan, et al.
Pharmacological Reports : PR|September 24, 2015
5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoidsPradeep Jayarajan, Ramakrishna Nirogi, Anil Shinde, et al.
European Journal of Pharmacology|July 16, 2011
Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory painRamakrishna Nirogi, Sugin Lal Jabaris, Pradeep Jayarajan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersVijay Benade, Anil Shinde, Rajesh Kumar Badange, et al.
Psychopharmacology|March 17, 2022
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterizationRamakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentRenny Abraham, Venkatesh Goura, Rajesh Kallepalli, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
European Journal of Pharmacology|May 11, 2013
α4β2* neuronal nicotinic receptor ligands (agonist, partial agonist and positive allosteric modulators) as therapeutic prospects for painRamakrishna Nirogi, Venkatesh Goura, Renny Abraham, et al.
Behavioural Pharmacology|October 14, 2025
5-Hydroxytryptamine 7 receptor agonist LP-211 in combination with gabapentin ameliorates neuropathic pain comorbidities associated with mechanical allodynia in diabetic and nerve-ligated ratsVenkatesh Goura, Pradeep Jayarajan, Anoop Kishore, et al.
Journal of Pharmacological and Toxicological Methods|May 12, 2012
Comparison of manual and automated filaments for evaluation of neuropathic pain behavior in ratsRamakrishna Nirogi, Venkatesh Goura, Dhanalakshmi Shanmuganathan, et al.
Pharmacological Reports : PR|September 24, 2015
5-HT6 receptor antagonist attenuates the memory deficits associated with neuropathic pain and improves the efficacy of gabapentinoidsPradeep Jayarajan, Ramakrishna Nirogi, Anil Shinde, et al.
European Journal of Pharmacology|July 16, 2011
Antinociceptive activity of α4β2* neuronal nicotinic receptor agonist A-366833 in experimental models of neuropathic and inflammatory painRamakrishna Nirogi, Sugin Lal Jabaris, Pradeep Jayarajan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
BiomarkersVijay Benade, Anil Shinde, Rajesh Kumar Badange, et al.
Psychopharmacology|March 17, 2022
Ropanicant (SUVN-911), an α4β2 nicotinic acetylcholine receptor antagonist intended for the treatment of depressive disorders: pharmacological, behavioral, and neurochemical characterizationRamakrishna Nirogi, Renny Abraham, Pradeep Jayarajan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentRenny Abraham, Venkatesh Goura, Rajesh Kallepalli, et al.
Pageof 1